Expertise in
22
conditions

Dr. Craig M. Kessler

Hematology
MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital
3800 Reservoir Rd NW, 
Washington, DC 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital
3800 Reservoir Rd NW, 
Washington, DC 

Overview

Craig Kessler is a Hematologist practicing medicine in Washington, Washington, D.c..

Dr. Kessler is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 7 clinical trials. Dr. Kessler is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in DC

Hospital Affiliations

Medstar Georgetown University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
Research Tissue Bank
Research Tissue Bank
Enrollment Status: Completed
Publish Date: July 05, 2019
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Molecular Biology of Familial Myeloproliferative Disorders
Molecular Biology of Familial Myeloproliferative Disorders
Enrollment Status: Completed
Publish Date: September 05, 2017
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

144 Total Publications

Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.
Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.
Journal: Genes and immunity
Published: September 25, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (6.7 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (0.1 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kieron Dunleavy is a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Dunleavy is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Burkitt Lymphoma, and Bone Marrow Aspiration. Dr. Dunleavy is currently accepting new patients.

Expertise in
16
conditions
Dr. Sharon A. Savage
Hematology | Oncology
Expertise in
16
conditions
Dr. Sharon A. Savage
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (6.1 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Aplastic Anemia, Pure Red Cell Aplasia, Congenital Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Frequently Asked Questions about Dr. Craig M. Kessler

How do I make an appointment with Dr. Craig M. Kessler?

You can book an appointment with Dr. Craig M. Kessler by calling their office at 202-444-2223. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig M. Kessler a top-rated expert for Blood Clots?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig M. Kessler is classified as an Elite expert for Blood Clots, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig M. Kessler specialize in?

While Dr. Craig M. Kessler is a Hematology, they have specific expertise in Blood Clots, Hemophilia A, and Acquired Hemophilia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Craig M. Kessler participate in research or clinical trials?

Yes. Dr. Craig M. Kessler has published 144 articles and abstracts on conditions like Blood Clots. You can view a list of Dr. Craig M. Kessler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig M. Kessler accept my insurance?

Dr. Craig M. Kessler accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 202-444-2223 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kessler's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile